Cynata Therapeutics (CYP) Investor presentation summary

Platform and technology

• Cymerus™ platform enables scalable production of mesenchymal stromal cells (MSCs) from a single blood donation, overcoming donor variability and scalability issues.

• iPSC-derived MSCs show superior consistency, potency, and immunomodulatory effects compared to donor-derived MSCs.

• Independent validation in Nature's npj Regenerative Medicine highlights enhanced regenerative and immune-balancing properties.

• Cymerus™ MSCs retain a 'younger' phenotype and demonstrate faster wound healing in vitro.

Clinical pipeline and milestones

• Four clinical programs underway, including advanced Phase 2 and 3 trials in osteoarthritis, acute graft vs host disease (aGvHD), kidney transplantation, and diabetic foot ulcers.

• Phase 3 osteoarthritis trial (CYP-004) is the world's largest MSC-based OA study, with results expected Q2 CY26.

• Phase 2 aGvHD trial (CYP-001) is global, randomized, and double-blind, with results also expected Q2 CY26.

• Kidney transplantation Phase 1/2 trial ongoing, with preliminary results from Cohort 1 due Q4 CY25.

• Diabetic foot ulcer Phase 1 trial showed 83.6% wound reduction versus 47.8% with standard care.

Market opportunity and commercial strategy

• Addressing high-burden diseases with large markets: osteoarthritis (US$11.6bn), aGvHD (US$600m), kidney transplantation (US$5.9bn), and diabetic foot ulcers (US$9.6bn).

• Positioned for global licensing, joint ventures, and pharma alliances, with potential for non-dilutive partnership revenue.

• First mover in a high-barrier, low-competition market with strong IP protection and FDA Orphan Drug designation.

• Trades at a discount to biotech peers despite advanced clinical pipeline and sector leadership.